Business Context and Reporting Period
This Form 8-K filing by Revelation Biosciences, Inc. (REVB) reports on the results of the Company's Annual Meeting of Stockholders held on July 14, 2023. The filing details the voting outcomes for director elections, equity plan amendments, and auditor ratification.
Key Financial Metrics
This filing is a current report regarding corporate governance events and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
A quorum was established with 2,309,314 shares present, representing greater than one-third of the 5,773,983 shares outstanding. The following proposals were approved:
- Proposal 1 (Election of Directors): Stockholders elected Jennifer Carver and Curt LaBelle as Class A directors to serve until the 2026 Annual Meeting.
- Proposal 2 (Equity Incentive Plan Amendment): Stockholders approved an amendment to the 2021 Equity Incentive Plan, increasing the number of reserved shares from 68,288 to 648,678.
- Proposal 3 (Auditor Ratification): Stockholders ratified the appointment of Baker Tilly US, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is strictly a record of shareholder voting actions.
Key Facts for Investor Verification
- Verify the impact of the 648,678 share increase in the 2021 Equity Incentive Plan on potential future dilution.
- Confirm the tenure of the newly elected directors (Jennifer Carver and Curt LaBelle) extending to the 2026 Annual Meeting.
- Note that the filing does not provide updated financial status; refer to the most recent 10-Q or 10-K for financial health.